Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: J Control Release. 2013 Jun 12;171(3):322–329. doi: 10.1016/j.jconrel.2013.06.001

Fig. 3.

Fig. 3

In vitro biologic activity of IL-2 within the PMLA-fusion nanobioconjugate. IL-2 activity was determined by incorporation of [3H]-thymidine into CTLL-2 cells incubated in the presence of varying concentrations of IL-2 fusion proteins and controls. Serial 1:3 dilutions of IL-2 equivalents ranging from 30 ng/ml to 0.13 ng/ml of anti-HER2/neu IgG3 (IgG3), anti-HER2/neu IgG3-(IL-2) [IgG3-(IL-2)], and PMLA-fusion nanobioconjugate P/mPEG/LOEt/IgG3-(IL-2)/AON(α4β1) were made in quadruplicate and incubated with CTLL-2 cells for 18 h followed by a 6-hour pulse of [3H]-thymidine. The error bars indicate the standard deviation.